arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2008-14-3-203-210arthyper-1230Research ArticleОБЗОРREVIEWБлокада альдостерона - новая стратегия лечения резистентной артериальной гипертензииAldosterone blockade, a new strategy in the treatment of resistant hypertensionБарановаЕ.BaranovaE.noemail@neicon.ruБольшаковаО.BolshakovaO.noemail@neicon.ruБерковичО.BerkovichO.noemail@neicon.ruСанкт-Петербургский государственный медицинский университет имени акад. И.П. ПавловаРоссияState Medical UniversityRussian Federation200828062008143203210Copyright © Баранова Е., Большакова О., Беркович О., 20082008Баранова Е., Большакова О., Беркович О.Baranova E., Bolshakova O., Berkovich O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/1230

В статье рассмотрена патогенетическая роль альдостерона в формировании феномена резистентной артериальной гипертензиии, а также вопросы его медикаментозной коррекции.

Pathogenetic role of aldosterone in resistant hypertension phenomenon and its possible correction are discussed. Key words: aldosterone, aldosteronism, resistant hypertension, aldosterone antagonists.

альдостеронгиперальдостеронизмрезистентная артериальная гипертензияантагонисты альдостеронаaldosteronealdosteronismresistant hypertensionaldosterone antagonistsReferencesALLHAT Officers and coordinators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002;288:2981-2997.ALLHAT Officers and coordinators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002;288:2981-2997.Hansson L, Zanchetti A, Carruthers S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-1762.Hansson L, Zanchetti A, Carruthers S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-1762.Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003; 289: 2073-2082.Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003; 289: 2073-2082.Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowing Treatment to Prevent Attack Trial (ALLHAT). J Clin Hypertens 2002; 4 (6): 393-404.Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowing Treatment to Prevent Attack Trial (ALLHAT). J Clin Hypertens 2002; 4 (6): 393-404.Calhoun DA, Jones D, Textor S, et al. Resistant Hypertension; Diagnosis, Evaluation, and Treatment. A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117:e510-526.Calhoun DA, Jones D, Textor S, et al. Resistant Hypertension; Diagnosis, Evaluation, and Treatment. A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117:e510-526.Moser M., Setano J. Resistant or difficult-to-control hypertension. N Engl J Med 2006; 355: 385-392.Moser M., Setano J. Resistant or difficult-to-control hypertension. N Engl J Med 2006; 355: 385-392.Rossi E., Regolisti G., Negro A., et al. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 2002; 15: 896-902.Rossi E., Regolisti G., Negro A., et al. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 2002; 15: 896-902.Mosso L, Carvajal C, Gonzales A, et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161-165.Mosso L, Carvajal C, Gonzales A, et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161-165.Nishizaka MK, Calhoun DA Use of aldosterone antagonists in resistant hypertension. J Clin Hypertens 2004; 6 (8): 458-560.Nishizaka MK, Calhoun DA Use of aldosterone antagonists in resistant hypertension. J Clin Hypertens 2004; 6 (8): 458-560.Подзолков В.И., Родионов А.В. Первичный гиперальдо-стеронизм: диагностика и лечение. Артериальная гипертензия 2004; 10 (2): 109-113.Подзолков В.И., Родионов А.В. Первичный гиперальдо-стеронизм: диагностика и лечение. Артериальная гипертензия 2004; 10 (2): 109-113.Conn JW. Presidential address Part I: painting background; Part II: primary aldosteronism - a new clinical syndrome. J Lab Clin Med 1955; 45: 3-17.Conn JW. Presidential address Part I: painting background; Part II: primary aldosteronism - a new clinical syndrome. J Lab Clin Med 1955; 45: 3-17.Kaplan N.M. The current epidemic of primary aldosteronism: causes and consequences. J Hypertens 2004; 22: 863-869.Kaplan N.M. The current epidemic of primary aldosteronism: causes and consequences. J Hypertens 2004; 22: 863-869.Izzo J.L., Black H.R. Hypertension primer. Dallas 2003; 532.Izzo J.L., Black H.R. Hypertension primer. Dallas 2003; 532.Ehrhart-Bornstein M., Lamounier-Zepter V., Schraven A., et al. Human adipocytes secrete mineralcorticoid-releasing factors. Proc Natl Acad Sci USA 2003; 100: 14211-14216.Ehrhart-Bornstein M., Lamounier-Zepter V., Schraven A., et al. Human adipocytes secrete mineralcorticoid-releasing factors. Proc Natl Acad Sci USA 2003; 100: 14211-14216.Calhoun D.A., Nishizaka M.K., Zaman M.A., et al. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 2004; 125: 112-117.Calhoun D.A., Nishizaka M.K., Zaman M.A., et al. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 2004; 125: 112-117.Benchetrik S., Bernheim J., Podjarny E. Normokalemic hyperaldosteronism in patients with resistant hypertension. Isr. Med Assoc J 2002; 4: 17-20.Benchetrik S., Bernheim J., Podjarny E. Normokalemic hyperaldosteronism in patients with resistant hypertension. Isr. Med Assoc J 2002; 4: 17-20.Eide I.K., Torjesen P.A., Drolsum A., et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004; 22: 2217-2226.Eide I.K., Torjesen P.A., Drolsum A., et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004; 22: 2217-2226.Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of lowdose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16: 925-930.Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of lowdose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16: 925-930.Baxter J.D., Young W.F., Webb P. Cardiovascular endocrinology: introduction. Endocr Rev 2003; 24 (3): 253-260.Baxter J.D., Young W.F., Webb P. Cardiovascular endocrinology: introduction. Endocr Rev 2003; 24 (3): 253-260.Stier J., Chander P.N., Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 2002; 10: 97-107.Stier J., Chander P.N., Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 2002; 10: 97-107.Folkow B. Structure and function of the arteries in hypertension. Am Heart J 1987; 114: 938-948.Folkow B. Structure and function of the arteries in hypertension. Am Heart J 1987; 114: 938-948.Folkow В., Ely D. Importance of the blood pressure-heart rate relationship. Blood Press 1998; 7: 133-138.Folkow В., Ely D. Importance of the blood pressure-heart rate relationship. Blood Press 1998; 7: 133-138.Clement D.L., Duprez D. Circulatory changes in muscle and skin arteries in primary hypertension. Hypertension 1984; 6 (2): III - 122 - III - 127Clement D.L., Duprez D. Circulatory changes in muscle and skin arteries in primary hypertension. Hypertension 1984; 6 (2): III - 122 - III - 127McVeigh GE, Allen PB, Morgan DR, et al. Nitric oxide modulation of blood vessel tone identified by arterial waveform analysis. Clin Sci 2001; 100: 387-393.McVeigh GE, Allen PB, Morgan DR, et al. Nitric oxide modulation of blood vessel tone identified by arterial waveform analysis. Clin Sci 2001; 100: 387-393.Aderson T.J., Uehata A., Gerhard M.D., et al. Close relation of endothelial function in the human coronary and peripheral circulation. J Am Coll Cardiol 1995; 26: 1235-1241.Aderson T.J., Uehata A., Gerhard M.D., et al. Close relation of endothelial function in the human coronary and peripheral circulation. J Am Coll Cardiol 1995; 26: 1235-1241.Lee K.W., Blann A.D., Lip G.Y. High pulse pressure and nondipping circadian blood pressure in patients with coronary artery disease: relationship to thrombogenesis and endothelial damage/dysfunction. Am J Hypertens 2005; 18: 104-115.Lee K.W., Blann A.D., Lip G.Y. High pulse pressure and nondipping circadian blood pressure in patients with coronary artery disease: relationship to thrombogenesis and endothelial damage/dysfunction. Am J Hypertens 2005; 18: 104-115.Duprez D.A. Role of the rennin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J Hypertens 2006; 24: 983-991.Duprez D.A. Role of the rennin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J Hypertens 2006; 24: 983-991.Calhoun DA, Nishizaka MK, Zaman MA, et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40: 892-896.Calhoun DA, Nishizaka MK, Zaman MA, et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40: 892-896.Rocha R., Rudolph A.E., Frierdich G.E., et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002; 283: H1802-H1810.Rocha R., Rudolph A.E., Frierdich G.E., et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002; 283: H1802-H1810.Bauersachs J., Fraccarollo D. Endothelial NO synthase target of aldosterone. Hypertension 2006; 48: 27-28.Bauersachs J., Fraccarollo D. Endothelial NO synthase target of aldosterone. Hypertension 2006; 48: 27-28.Nagata D., Takahashi M., Sawai K., et al. Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension 2006; 48: 165-171.Nagata D., Takahashi M., Sawai K., et al. Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension 2006; 48: 165-171.Bauersachs J., Heck M., Fraccarollo D., et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction; role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 2002; 39: 351-358.Bauersachs J., Heck M., Fraccarollo D., et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction; role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 2002; 39: 351-358.Taddei S., Virdis A., Mattei P., et al. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993; 21: 929-933.Taddei S., Virdis A., Mattei P., et al. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993; 21: 929-933.Wehling M. Effects of aldosterone and mineralcorticoid receptor blockade on intracellular electrolytes. Heart Fail Rev 2005; 10: 39-46.Wehling M. Effects of aldosterone and mineralcorticoid receptor blockade on intracellular electrolytes. Heart Fail Rev 2005; 10: 39-46.Schiffrin E.L. Effects of aldosterone on the vasculature. Hypertension 2006; 47: 312-318.Schiffrin E.L. Effects of aldosterone on the vasculature. Hypertension 2006; 47: 312-318.Marumo Т., Uchimura H., Hayashi M., et al. Aldosterone impairs bone marrow-derived progenitor cell formation. Hypertension 2006; 48: 490-496.Marumo Т., Uchimura H., Hayashi M., et al. Aldosterone impairs bone marrow-derived progenitor cell formation. Hypertension 2006; 48: 490-496.Park J.В., Schiffrin E.L. Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension. J Hypertens 2001; 19: 921-930.Park J.В., Schiffrin E.L. Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension. J Hypertens 2001; 19: 921-930.Duprez D.A., De Buyzere M.L., Reitzshel E.R., et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998; 19: 1371-1376.Duprez D.A., De Buyzere M.L., Reitzshel E.R., et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998; 19: 1371-1376.Safar M.E., Cattan V., Lacolley P., et al. Aldosterone synthase gene polymorphism, stroke volume and age-related changes in aortic pulse wave velocity in subjects with hypertension. J Hypertens 2005; 23: 1159-2266.Safar M.E., Cattan V., Lacolley P., et al. Aldosterone synthase gene polymorphism, stroke volume and age-related changes in aortic pulse wave velocity in subjects with hypertension. J Hypertens 2005; 23: 1159-2266.Smidt B.M., Summer U., Fleischmann I., Schlaich M., Delles C., Schmieder RE. Rapid nongenomic effects of aldosterone on the renal vasculature in humans. Hypertension 2006; 47(4): 650-5.Smidt B.M., Summer U., Fleischmann I., Schlaich M., Delles C., Schmieder RE. Rapid nongenomic effects of aldosterone on the renal vasculature in humans. Hypertension 2006; 47(4): 650-5.Epstein M., Williams G.H., Weinberger M., et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940-951.Epstein M., Williams G.H., Weinberger M., et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940-951.Gomez-Sanchez E.P. Intracerebroventricular infusion of aldosterone induces hypertension in rats. Endocrinology 1986; 118:819-823.Gomez-Sanchez E.P. Intracerebroventricular infusion of aldosterone induces hypertension in rats. Endocrinology 1986; 118:819-823.Ylitalo A., Airaksinen K.E., Hautanen A. et al. Baroreflex sensitivity and variants of the rennin angiotensin system genes. J Am Coll Cardiol 2000; 35: 194-200.Ylitalo A., Airaksinen K.E., Hautanen A. et al. Baroreflex sensitivity and variants of the rennin angiotensin system genes. J Am Coll Cardiol 2000; 35: 194-200.Pitt В., Fonarow G.C., Gheorghiade M., et al. Improving outcomes in post-acute myocardial infarction heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade. Am J Cardiol 2006; 97: 26F-33F.Pitt В., Fonarow G.C., Gheorghiade M., et al. Improving outcomes in post-acute myocardial infarction heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade. Am J Cardiol 2006; 97: 26F-33F.Takeda Y. Vascular synthesis of aldosterone: role in hypertension. Mol Cell Endocrinol 2004; 217: 75-79.Takeda Y. Vascular synthesis of aldosterone: role in hypertension. Mol Cell Endocrinol 2004; 217: 75-79.White WB, Duprez D, St Hillaire R, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41: 1021-1026.White WB, Duprez D, St Hillaire R, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41: 1021-1026.Matsumura K., Fujii K.,Oniki H., et al. Role of aldosterone in left ventricular hypertrophy in hypertension. Am J Hypertens 2006; 19: 13.Matsumura K., Fujii K.,Oniki H., et al. Role of aldosterone in left ventricular hypertrophy in hypertension. Am J Hypertens 2006; 19: 13.Rocha R., Stier C.T. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocr Metab 2001; 12:308-314.Rocha R., Stier C.T. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocr Metab 2001; 12:308-314.Robert V., van Thiem N., Cheav S.L. et al. Increased cardiac types I and III collagen mRNA in aldosterone-salt hypertension. Hypertension 1994; 24: 30-36.Robert V., van Thiem N., Cheav S.L. et al. Increased cardiac types I and III collagen mRNA in aldosterone-salt hypertension. Hypertension 1994; 24: 30-36.Braunwald's heart disease: a textbook of cardiovascular medicine. 8th ed. Philadelphia. USA 2008: 2183.Braunwald's heart disease: a textbook of cardiovascular medicine. 8th ed. Philadelphia. USA 2008: 2183.Dluhy R.G., Williams G.H. Aldosterone - villain or bystander? N Engl J Med 2004; 351: 8-10.Dluhy R.G., Williams G.H. Aldosterone - villain or bystander? N Engl J Med 2004; 351: 8-10.Calhoun DA, Nishizaka MK, Zaman MA, et al. High prevalence of primary aldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40: 892-896.Calhoun DA, Nishizaka MK, Zaman MA, et al. High prevalence of primary aldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40: 892-896.Gallay BJ, Ahmad S, Xu L, et al. Screening for primary aldosteronism without discontinuing hypertensive medications; plasma aldosterone-renin ratio. Am J Kidney Dis 2001; 37: 699-705.Gallay BJ, Ahmad S, Xu L, et al. Screening for primary aldosteronism without discontinuing hypertensive medications; plasma aldosterone-renin ratio. Am J Kidney Dis 2001; 37: 699-705.Eide IK, Torjesen PA, Droisum A, et al. Low-renin status in therapy-resistant hypertension; a clue to efficient treatment. J Hypertens 2004; 22: 2217-2226.Eide IK, Torjesen PA, Droisum A, et al. Low-renin status in therapy-resistant hypertension; a clue to efficient treatment. J Hypertens 2004; 22: 2217-2226.Grim CE. Low-renin "essential" hypertension: a variant of primary aldosteronism? Arch Intern Med 1975; 135: 347-350.Grim CE. Low-renin "essential" hypertension: a variant of primary aldosteronism? Arch Intern Med 1975; 135: 347-350.Ramsay LE, Silas JH, Freestone S. Diuretic treatment of resistant hypertension. BMJ 1980; 281: 1101-1103.Ramsay LE, Silas JH, Freestone S. Diuretic treatment of resistant hypertension. BMJ 1980; 281: 1101-1103.Ouzan J., Perault C., Lincoff A.M. et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002; 15: 333-339.Ouzan J., Perault C., Lincoff A.M. et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002; 15: 333-339.Saha C, Eckert GJ, Ambrosius WT, et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005; 46: 481-487.Saha C, Eckert GJ, Ambrosius WT, et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005; 46: 481-487.Krum H., Nolly H., Workman D., et al. Efficacy of eplerenone added to rennin-angiotensin blockade in hypertensive patients. Hypertension 2002; 40:117-123.Krum H., Nolly H., Workman D., et al. Efficacy of eplerenone added to rennin-angiotensin blockade in hypertensive patients. Hypertension 2002; 40:117-123.Weinberger MH, White WB, Rullope L-M, et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J 2005; 150: 426-433.Weinberger MH, White WB, Rullope L-M, et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J 2005; 150: 426-433.White P.C. Aldosterone: Direct effects on and production by the heart. J Clin Endocr Metab 2003; 88: 2376.White P.C. Aldosterone: Direct effects on and production by the heart. J Clin Endocr Metab 2003; 88: 2376.White WB Ambulatory blood pressure monitoring as an investigative tool for characterizing resistant hypertension and its rational treatment J Clin Hypetens 2007; 9(1, suppl. 1): 25-30.White WB Ambulatory blood pressure monitoring as an investigative tool for characterizing resistant hypertension and its rational treatment J Clin Hypetens 2007; 9(1, suppl. 1): 25-30.Pitt В., Ahmed A., Love T. et al. History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure. Hypertension 2008; 52: 271-278.Pitt В., Ahmed A., Love T. et al. History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure. Hypertension 2008; 52: 271-278.Parodi G., Carrabba N., Santoro G. et al. Heart failure and left ventricular remodeling after reperfused acute myocardial infarction in patients with hypertension. Hypertension 2006; 47: 706-710.Parodi G., Carrabba N., Santoro G. et al. Heart failure and left ventricular remodeling after reperfused acute myocardial infarction in patients with hypertension. Hypertension 2006; 47: 706-710.Pitt B. Aldosterone blockade in patients with acute myocardial infarction. Circulation 2003; 107: 2525-2527.Pitt B. Aldosterone blockade in patients with acute myocardial infarction. Circulation 2003; 107: 2525-2527.Pitt В., Reichek N., Willenbrock R. et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003; 108: 1831-1838.Pitt В., Reichek N., Willenbrock R. et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003; 108: 1831-1838.Ahmed A., Zannad F., Love T. et al. A propensity matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur Heart J 2007; 28: 1134-1143.Ahmed A., Zannad F., Love T. et al. A propensity matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur Heart J 2007; 28: 1134-1143.

The authors declare that there are no conflicts of interest present.